Clarithromycin Shortage: What Providers and Prescribers Need to Know in 2026

For providers managing patients with respiratory infections, H. pylori disease, or MAC prophylaxis, Clarithromycin remains a cornerstone therapy. But in 2026, intermittent availability issues continue to affect patient access — even without a formal shortage designation.

This briefing covers the current state of Clarithromycin supply, prescribing considerations when stock is limited, cost and access factors, and tools to help your patients locate their medication.

Current Supply Status

As of early 2026, Clarithromycin is not listed on the FDA or ASHP drug shortage databases. However, providers should be aware that:

• Regional and pharmacy-level stock-outs continue to be reported, particularly during respiratory illness season (October–March)
• The brand-name product (Biaxin) has been largely discontinued; all supply depends on generic manufacturers including Teva, Sandoz, Sun Pharma, and Aurobindo
• Supply chain concentration — with most APIs sourced from overseas facilities — creates vulnerability to disruptions
• Automated pharmacy inventory systems may understock Clarithromycin in locations with low recent dispensing volume

Timeline: How We Got Here

Clarithromycin has experienced periodic availability challenges over the past several years:

• 2018: FDA issued a Drug Safety Communication warning of increased cardiovascular mortality risk in patients with heart disease, which modestly shifted prescribing patterns away from Clarithromycin
• 2022–2023: Broad antibiotic supply pressures during the "tripledemic" (COVID-19, influenza, RSV) affected availability of multiple oral antibiotics including Clarithromycin and Amoxicillin
• 2024–2025: Supply stabilized as manufacturers expanded production capacity. No formal shortage was declared, but localized stock-outs persisted
• 2026: Supply is generally stable, though seasonal demand fluctuations continue to cause periodic access issues

Prescribing Implications

Indications Where Clarithromycin Remains Preferred

While many respiratory infections can be treated with alternative antibiotics, there are clinical scenarios where Clarithromycin offers distinct advantages:

• H. pylori eradication: Clarithromycin-based triple therapy (with Amoxicillin and a PPI) remains a first-line regimen per ACG guidelines, though Bismuth quadruple therapy is an alternative if Clarithromycin resistance is suspected
• MAC prophylaxis and treatment: Clarithromycin is preferred over Azithromycin in treatment regimens for disseminated MAC disease in HIV-positive patients
• Community-acquired pneumonia: In patients who require a macrolide and cannot tolerate Azithromycin, Clarithromycin remains a viable option

The 2018 FDA Cardiovascular Warning

Prescribers should continue to factor in the 2018 FDA safety communication regarding increased risk of cardiovascular events and mortality in patients with coronary heart disease. Key points:

• Based on a 10-year follow-up of the CLARICOR trial, a 2-week course of Clarithromycin was associated with an unexpected increase in all-cause mortality
• The FDA advises considering alternative antibiotics in patients with known coronary artery disease
• This warning does not apply to the general population or patients without established heart disease

Drug Interaction Considerations

Clarithromycin is a potent CYP3A4 and P-glycoprotein inhibitor, creating clinically significant interactions with:

• Contraindicated combinations: Cisapride, pimozide, ergotamine/dihydroergotamine, lovastatin, simvastatin, lomitapide, and colchicine (in patients with hepatic/renal impairment)
• High-risk interactions: Warfarin (increased INR), digoxin (toxicity risk), carbamazepine, benzodiazepines (midazolam, triazolam), calcium channel blockers, cyclosporine, and tacrolimus
• QT-prolonging agents: Additive risk when combined with other QT-prolonging drugs

Azithromycin has a significantly lower interaction profile and may be preferable in polypharmacy patients. For a comprehensive review, see Clarithromycin drug interactions.

Availability Picture for 2026

Key availability data points for prescribers:

• Formulations available: Immediate-release tablets (250 mg, 500 mg), extended-release tablets (500 mg), oral suspension (125 mg/5 mL, 250 mg/5 mL)
• Generic status: Fully generic; no active brand-name product in the U.S. market
• Manufacturer base: 4+ generic manufacturers actively producing
• Distribution: Available at all major chain and independent pharmacies, though individual location stock may vary

Cost and Access

Cost can be a barrier for uninsured or underinsured patients:

• Retail cash price: $14–$148 for a 14-day course of 500 mg immediate-release tablets
• With discount coupons: $16–$25 (GoodRx, SingleCare, RxSaver)
• Extended-release: $52–$243 retail; $52–$66 with coupons
• Insurance coverage: Generally Tier 1 or Tier 2 on most formularies; rarely requires prior authorization
• Patient assistance: No dedicated manufacturer PAP exists. Refer patients to NeedyMeds.org or RxAssist.org for general generic drug assistance programs

For provider-specific cost guidance, see how to help patients save money on Clarithromycin.

Tools and Resources for Providers

Medfinder for Providers offers real-time pharmacy availability data that can help you and your staff:

• Verify stock before sending a prescription to a specific pharmacy
• Identify alternative pharmacies when a patient's usual pharmacy is out of stock
• Provide patients with actionable next steps rather than leaving them to call around on their own

Additional resources:

• FDA Drug Shortage Database: accessdata.fda.gov for official shortage designations
• ASHP Drug Shortages: ashp.org/drug-shortages for clinical management recommendations
• Antibiotic stewardship resources: CDC's core elements of outpatient antibiotic stewardship

Looking Ahead

The macrolide antibiotic landscape is unlikely to change dramatically in the near term. Clarithromycin's role will continue to be shaped by:

• Evolving H. pylori resistance patterns — rising Clarithromycin resistance in some regions may shift first-line therapy toward Bismuth quadruple regimens
• Cardiovascular safety data — ongoing post-marketing surveillance related to the 2018 FDA warning
• Generic manufacturing capacity — additional manufacturers entering the market should improve supply resilience
• Antibiotic stewardship pressure — appropriate prescribing remains essential to maintaining efficacy

Final Thoughts

While Clarithromycin is not in formal shortage, the practical reality for patients can differ from the national picture. Providers play a key role in bridging this gap — by verifying availability before prescribing, proactively discussing alternatives, and directing patients to tools like Medfinder that make finding medication less burdensome.

For more clinical context, review our posts on helping patients find Clarithromycin in stock and Clarithromycin alternatives.